AC
PACB icon

Athos Capital’s Pacific Biosciences PACB Stock Holding History

Athos Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-69,420
Closed -$357K – 28
2019
Q4 		$357K Buy
+69,420
New +$353K 0.36% 31
2019
Q3 		– Sell
-49,380
Closed -$299K – 33
2019
Q2 		$299K Sell
49,380
-156,243
-76% -$1.1M 0.13% 37
2019
Q1 		$1.5M Buy
205,623
+133,666
+186% +$967K 0.97% 15
2018
Q4 		$532K Buy
+71,957
New +$456K 0.53% 18

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
KLCMU
Kite Lake Capital Management (UK) London, United Kingdom $290M AUM 183.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Athos Capital's PACB Position: Q1 2020 in Review

Athos Capital sold out of Pacific Biosciences (PACB) in Q1 2020, closing a stake of 69,420 shares — an estimated $357K sold.

Athos Capital first reported a position in PACB in Q4 2018 and held it in 4 quarters. The position peaked at $1.5M in Q1 2019. 132 funds tracked by Wall St. Rank hold PACB as of Q1 2020.

  • Athos Capital reported no remaining Pacific Biosciences position as of Q1 2020 after selling out during the quarter.
  • Athos Capital sold 69,420 Pacific Biosciences shares in Q1 2020, an estimated $357K.
  • Athos Capital first reported a position in Pacific Biosciences in Q4 2018 and held it in 4 quarters.
  • Athos Capital's Pacific Biosciences position peaked at $1.5M in Q1 2019.
  • 132 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2020.

Based on Athos Capital's 13F filing for Q1 2020, filed 12 May 2020.